Literature DB >> 15293094

Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate.

Howard Amital1, Yaakov H Applbaum, Lena Vasiliev, Alan Rubinow.   

Abstract

This case presents a patient with hypertrophic osteoarthropathy of the lower extremities that developed secondary to congenital cyanotic heart disease. The major clinical manifestation was severe bilateral leg pain. The pain that was debilitating in nature completely resolved following a single administration of 60 mg pamidronate. Hypertrophic osteoarthropathy (HOA) is an acquired, uncommon disorder of obscure etiology. It has been described mainly in association with chronic suppurative pulmonary diseases, bronchogenic carcinoma and lung metastases, cystic fibrosis, and cyanotic congenital malformations of the heart.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15293094     DOI： 10.1007/s10067-004-0941-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  11 in total

1.  Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

Authors:  S P Luckman; D E Hughes; F P Coxon; R Graham; G Russell; M J Rogers
Journal:  J Bone Miner Res       Date:  1998-04       Impact factor: 6.741

2.  Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma.

Authors:  T Suzuma; T Sakurai; G Yoshimura; T Umemura; T Tamaki; T Yoshimasu; Y Naito
Journal:  Anticancer Drugs       Date:  2001-10       Impact factor: 2.248

3.  Hypertrophic osteoarthropathy: endothelium and platelet function.

Authors:  F Silveri; R De Angelis; F Argentati; D Brecciaroli; S Muti; C Cervini
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

4.  Vascular endothelial growth factor and hypertrophic osteoarthropathy.

Authors:  L H Silveira; M Martínez-Lavín; C Pineda; M C Fonseca; C Navarro; A Nava
Journal:  Clin Exp Rheumatol       Date:  2000 Jan-Feb       Impact factor: 4.473

5.  Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.

Authors:  E van Beek; E Pieterman; L Cohen; C Löwik; S Papapoulos
Journal:  Biochem Biophys Res Commun       Date:  1999-10-14       Impact factor: 3.575

6.  Cardiogenic hypertrophic osteoarthropathy.

Authors:  M Martinez-Lavin
Journal:  Clin Exp Rheumatol       Date:  1992 May-Jun       Impact factor: 4.473

7.  Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis.

Authors:  Luke A Garske; Scott C Bell
Journal:  Chest       Date:  2002-04       Impact factor: 9.410

8.  The spectrum of soft tissue and skeletal abnormalities of hypertrophic osteoarthropathy.

Authors:  C Pineda; C Fonseca; M Martinez-Lavin
Journal:  J Rheumatol       Date:  1990-05       Impact factor: 4.666

9.  A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor.

Authors:  Yoshiyuki Abe; Satoshi Kurita; Yasuyuki Ohkubo; Hiroshi Usui; Toshinori Hashizume; Masato Nakamura; Yoshito Ueyama; Tadahiko Fujino
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

Review 10.  Bisphosphonates: new indications and methods of administration.

Authors:  Ian R Reid
Journal:  Curr Opin Rheumatol       Date:  2003-07       Impact factor: 5.006
View more
  9 in total

1.  Hypertrophic Osteoarthropathy: an Unusual Cause of Knee Pain and Recurrent Effusion.

Authors:  Ishaan Swarup; Douglas N Mintz; Eduardo A Salvati
Journal:  HSS J       Date:  2016-08-30

Review 2.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

3.  Hypertrophic osteoarthropathy presenting as unilateral cellulitis with successful treatment using pamidronate disodium.

Authors:  Sebastian G Bernardo; Jason J Emer; Mark E Burnett; Marsha Gordon
Journal:  J Clin Aesthet Dermatol       Date:  2012-09

4.  Treatment of hypertrophic osteoarthropathy in the case of pulmonary metastasis secondary-to-nasopharyngeal carcinoma with zoledronic acid: an enlightening experience.

Authors:  Nikhil Sonthalia; Kabita Mukherjee; Avishek Saha; Arunansu Talukdar
Journal:  BMJ Case Rep       Date:  2012-11-11

Review 5.  Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy.

Authors:  Sheila Nguyen; Mehrnaz Hojjati
Journal:  Clin Rheumatol       Date:  2010-10-09       Impact factor: 2.980

6.  Hypertrophic osteoarthropathy and congenital heart disease: this is not casual.

Authors:  Ester Ferreira; Isabel Camões
Journal:  BMJ Case Rep       Date:  2013-09-18

Review 7.  Pamidronate treatment in rheumatology practice: a comprehensive review.

Authors:  Gleb Slobodin; Itzhak Rosner; Joy Feld; Doron Rimar; Michael Rozenbaum; Nina Boulman; Majed Odeh
Journal:  Clin Rheumatol       Date:  2009-08-19       Impact factor: 2.980

8.  Aminobisphosphonate stimulates bone regeneration and enforces consolidation of titanium implant into a new rat caudal vertebrae model.

Authors:  József Blazsek; Csaba Dobó Nagy; István Blazsek; Rita Varga; Bálint Vecsei; Pál Fejérdy; Gábor Varga
Journal:  Pathol Oncol Res       Date:  2009-03-07       Impact factor: 3.201

9.  Clinical management of pain in advanced lung cancer.

Authors:  Claribel P L Simmons; Nicholas Macleod; Barry J A Laird
Journal:  Clin Med Insights Oncol       Date:  2012-10-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.